Loi, S., Hamilton, E. P., Jhaveri, K. L., Anders, C. K., Schmid, P., Dai, M., Ruiz-Borrego, M., Pádua, C. A. J. D., Zurawski, B., Zamagni, C., Gümüş, M., Gupta, S., Boston, S. R., Konpa, A., Darilay, A., Fabbri, G., André, F. (2026). Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1012